MHRA updates canagliflozin lower limb amputation warning

The Medicines and Healthcare products Regulatory Agency (MHRA), which regulates drugs and devices in the UK, has updated its advice concerning the increased risk of lower limb amputation associated with canaglifozin, a drug used to treat type 2 diabetes.
To read the whole article click on the headline